title: Phase II study of pyrazoloacridine in metastatic renal cell carcinoma.
authors.affiliation: Grant/Riverside Hospital, Columbus, OH, USA.
authors.forename: J P
authors.initials: JP
authors.lastname: Kuebler
authors.forename: G W
authors.initials: GW
authors.lastname: King
authors.forename: P
authors.initials: P
authors.lastname: Triozzi
authors.forename: T
authors.initials: T
authors.lastname: Moore
authors.forename: E H
authors.initials: EH
authors.lastname: Kraut
mesh_terms: D000166:Acridines / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000380:Agranulocytosis / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000166:Acridines; D000970:Antineoplastic Agents; D011720:Pyrazoles; C064541:NSC 366140